CIRC (01763) signs a "Strategic Cooperation Agreement" with CNNC Capital to empower high-quality development with financial capital.
China National Nuclear Corporation (01763) announced that on November 27th, at the Second Nuclear Technology Application Industry Chain Action Conference hosted by China National Nuclear Corporation Limited and the China Isotope and Radiation Industry Association, China National Nuclear Corporation signed a "Strategic Cooperation Agreement" with China National Nuclear Corporation Capital Holding Limited (CNNC Capital).
CIRC (01763) announced on November 27th that, at the second Nuclear Technology Application Industry Chain Action Conference hosted by China Nuclear Industry Group Co., Ltd. and China Isotope and Radiation Industry Association, CIRC signed a "Strategic Cooperation Agreement" with China Nuclear Industry Group Capital Holdings Co., Ltd. (CNIGC Capital).
According to the "Strategic Cooperation Agreement", the two parties will focus on promoting the integration of the nuclear technology application industry chain, breaking through key technological bottlenecks, and cultivating new productive forces as core goals. By sharing resources and complementing each other's advantages, they will deepen cooperation in mergers and acquisitions, establishing new companies, equity investments, securities business, and other aspects to build a new pattern of coordinated development between technology and finance, industry and finance, and empower CIRC with financial capital to achieve high-quality development.
Related Articles

HK Stock Market Move | IMMUNEONCO-B(01541) rose over 9% in the afternoon. The phase III clinical trial protocol for IMM0306 has obtained approval from the Center for Drug Evaluation (CDE).

The pharmaceutical industry continues to increase innovation, and we are optimistic about the Chinese medicine market's growth potential in 2026.

HAITONG INT'L: The overseas innovative drug industry chain is showing a structural recovery trend.
HK Stock Market Move | IMMUNEONCO-B(01541) rose over 9% in the afternoon. The phase III clinical trial protocol for IMM0306 has obtained approval from the Center for Drug Evaluation (CDE).

The pharmaceutical industry continues to increase innovation, and we are optimistic about the Chinese medicine market's growth potential in 2026.

HAITONG INT'L: The overseas innovative drug industry chain is showing a structural recovery trend.

RECOMMEND

Hong Kong Stock Buyback Wave Persists, 247 Listed Companies Repurchase Over HKD 150 Billion This Year
27/11/2025

Mingyu Pharmaceutical Files With HKEX: Ongoing Net Losses Since Inception, No Revenue From Commercial Product Sales
27/11/2025

“Affordability Crisis”! Consumer Confidence Falls To Second Lowest Since The Pandemic, U.S. Retail Slumps
27/11/2025


